These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33893084)

  • 1. Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.
    Suenaga M; Zhang WU; Mashima T; Schirripa M; Cao S; Okazaki S; Berger MD; Miyamoto Y; Barzi A; Yamaguchi T; Lenz HJ
    Cancer Genomics Proteomics; 2021; 18(3):317-324. PubMed ID: 33893084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Ning Y; Cremolini C; Antoniotti C; Borelli B; Mashima T; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Lonardi S; Yamaguchi T; Falcone A; Loupakis F; Lenz HJ
    Clin Colorectal Cancer; 2018 Jun; 17(2):e395-e414. PubMed ID: 29606345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5.
    Nishikawa G; Kawada K; Nakagawa J; Toda K; Ogawa R; Inamoto S; Mizuno R; Itatani Y; Sakai Y
    Cell Death Dis; 2019 Mar; 10(4):264. PubMed ID: 30890699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
    Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
    Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.
    Suenaga M; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Heinemann V; Lenz HJ
    Eur J Cancer; 2019 Jan; 107():100-114. PubMed ID: 30554073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?
    Ayhan M; Turan N; Köstek O; Tufan G; Tataroğlu Özyükseler D; Odabas H; Sakin A; Turan M; Sürmeli H; Yıldırım ME
    Curr Probl Cancer; 2021 Jun; 45(3):100670. PubMed ID: 33129567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.
    Matsusaka S; Hanna DL; Ning Y; Yang D; Cao S; Berger MD; Miyamoto Y; Suenaga M; Dan S; Mashima T; Seimiya H; Zhang W; Lenz HJ
    Cancer Sci; 2020 Feb; 111(2):441-450. PubMed ID: 31821662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
    Miyamoto Y; Schirripa M; Suenaga M; Cao S; Zhang W; Okazaki S; Berger MD; Matsusaka S; Yang D; Ning Y; Baba H; Loupakis F; Lonardi S; Pietrantonio F; Borelli B; Cremolini C; Yamaguchi T; Lenz HJ
    PLoS One; 2020; 15(9):e0239439. PubMed ID: 32970737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
    Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
    Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
    Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
    Yang Y; Xu L; Wang D; Hui B; Li X; Zhou Y; Chen X; Gu Y
    Immunotherapy; 2021 Nov; 13(16):1317-1323. PubMed ID: 34369830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer.
    Carter NJ
    Drugs Aging; 2014 Jan; 31(1):67-78. PubMed ID: 24276917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib: A Review in Metastatic Colorectal Cancer.
    Dhillon S
    Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
    Liu Y; Lyu J; Bell Burdett K; Sibley AB; Hatch AJ; Starr MD; Brady JC; Hammond K; Marmorino F; Rossini D; Goldberg RM; Falcone A; Cremolini C; Owzar K; Ivanova A; Moore DT; Lee MS; Sanoff HK; Innocenti F; Nixon AB
    Mol Cancer Ther; 2020 Oct; 19(10):2146-2154. PubMed ID: 32747417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
    Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
    Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
    J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
    Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
    Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.